Loading...

E-therapeutics Plc

ETX.L•LSE
Healthcare
Biotechnology
£9.00
£-0.65(-6.74%)

E-therapeutics Plc (ETX.L) Stock Overview

Explore E-therapeutics Plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap56.4M
P/E Ratio-4.71
EPS (TTM)$-0.02
ROE-0.41%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$6.75

ETX.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of E-therapeutics Plc (ETX.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $6.75.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.71 and a market capitalization of 56.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ETX.LStats details for ETX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ETX.LAnalyst Recommendations details for ETX.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.

CEO

Ahmad Ali Mortazavi

Employees

34

Headquarters

4 Kingdom Street, London

Founded

2007

Frequently Asked Questions

;